Skip to content
Partners4Access
Expert global consultancy specializing in access for orphan drugs
Partners4Access
  • Home
  • About us
    • Press releases
    • Meet the team
    • Careers
  • Services
  • Case studies
    • Case Study #1
    • Case Study #2
    • Case Study #3
  • Enlightened Opinion
    • Publications/White Papers
    • Webinars
  • Resources
    • Gene Therapy Mind Map
    • Podcasts
    • Blogs
  • Contact
Search:
  • Home
  • About us
    • Press releases
    • Meet the team
    • Careers
  • Services
  • Case studies
    • Case Study #1
    • Case Study #2
    • Case Study #3
  • Enlightened Opinion
    • Publications/White Papers
    • Webinars
  • Resources
    • Gene Therapy Mind Map
    • Podcasts
    • Blogs
  • Contact

Daily Archives: January 4, 2018

You are here:
  1. Home
  2. 2018
  3. January
  4. 04

Spark Therapeutics Announces $850 000 price tag of gene therapy treatment Luxturna

Publications/White PapersBy NickJanuary 4, 2018

Spark Therapeutics has announced its recently approved Luxturna (voretigene neparvovec-rzyl), a gene therapy treatment for biallelic RPE65 mutation-associated retinal dystrophy will cost $425 000 per eye, or $850 000 in total, in the U.S. This is below the $1 million price tag that was originally speculated. Spark Therapeutics is also working with Harvard Pilgrim, a…

TwitterInstagramLinkedin

All Rights Reserved © Privacy Partners 4 Access 2020

Go to Top